Prevalence of Human Papillomavirus in the Oral Cavity/Oropharynx in a Large Population of Children and Adolescents
- 1 September 2007
- journal article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 26 (9) , 836-840
- https://doi.org/10.1097/inf.0b013e318124a4ae
Abstract
Human papillomavirus (HPV) in the oral cavity or oropharynx is associated with an increased risk of laryngeal papillomatosis, head and neck cancer, and cervical and other genital cancers. We evaluated the prevalence of HPV DNA in the oral cavity/oropharynx in a cross section of children aged 2 weeks to 20 years. A risk factor questionnaire and oral exfoliated cells were collected from children (N = 1235). HPV DNA was detected using PCR, dot blot hybridization, and DNA sequencing. The HPV prevalence was 1.9% in the oral cavity/oropharynx of children. A bimodal age distribution was observed with the highest HPV prevalence in the youngest and oldest groups: 2.5% aged <1 year, 0.8% aged 1 to 4 years, 1.2% aged 5 to 11 years, 1.5% in aged 12 to 15 years, and 3.3% in aged 16 to 20 years. The prevalence of the HPV quadrivalent vaccine types (HPV-6, 11, 16, 18) reached 0.9% in the 16- to 20-year age group. In this age group, female gender [odds ratio (OR): 6.9, P = 0.04], genital warts (OR: 19.3, P < 0.01), and current smoker (OR: 6.5, P = 0.01) were associated with a higher risk of being detected with an oral HPV infection. No risk factors in parents were identified with transmission of HPV to infants. The age-specific prevalence rates of HPV in this large cross section of children and adolescents demonstrate that HPV infection is acquired gradually in childhood. These data support a target age for HPV vaccination before puberty to prevent serious HPV-related genital and oral diseases.Keywords
This publication has 20 references indexed in Scilit:
- Recurrent respiratory papillomatosis: pathogenesis to treatmentCurrent Opinion in Otolaryngology & Head and Neck Surgery, 2005
- Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialThe Lancet Oncology, 2005
- Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialThe Lancet, 2004
- Human Papillomavirus in Oral Exfoliated Cells and Risk of Head and Neck CancerJNCI Journal of the National Cancer Institute, 2004
- The Epidemiology of Cervical CancerThe Cancer Journal, 2003
- A Controlled Trial of a Human Papillomavirus Type 16 VaccineNew England Journal of Medicine, 2002
- Human papillomavirus in the oral cavities of children and adolescentsOral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 2001
- Low risk of perinatal transmission of human papillomavirus: Results from a prospective cohort studyAmerican Journal of Obstetrics and Gynecology, 1998
- Perinatal infection and persistence of human papillomavirus types 16 and 18 in infantsJournal of Medical Virology, 1995
- Laryngeal papillomas in infants and children: Relationship to maternal venereal wartsJournal of Nurse-Midwifery, 1991